Several studies suggest that inhibiting Nrf2-related antioxidant processes may be a practical and promising treatment strategy for inducing prooxidizing effects in the cancer cell microenvironment and triggering ROS-dependent cell death in various human cancers [213, 214]. The gene discussed is NFE2L2; the disease is cancer.